Edition:
United Kingdom

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

49.85USD
8:30pm BST
Change (% chg)

$1.90 (+3.96%)
Prev Close
$47.95
Open
$48.45
Day's High
$51.65
Day's Low
$47.85
Volume
219,441
Avg. Vol
286,609
52-wk High
$68.05
52-wk Low
$26.10

Select another date:

Wed, Jun 27 2018

GBT's drug meets trial goal, investors skeptical of speedy approval

Global Blood Therapeutics Inc's sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated review from health regulators pushed its shares down 12 percent.

UPDATE 3-GBT's drug meets trial goal, investors skeptical of speedy approval

* Shares fall as much as 12 pct (Adds details from conference call, analyst comments; updates share move)

Global Blood Therapeutics' sickle cell disease drug succeeds in trial

June 27 Global Blood Therapeutics Inc said on Wednesday its experimental drug met the main goal of a late-stage trial testing it in patients with sickle cell disease.

BRIEF-GBT Q1 Loss Per Share $0.87

* GBT REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Global Blood Therapeutics ‍priced underwritten public offering of 4.0 mln shares of its common stock

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK

BRIEF-Global Blood Therapeutics Announces Proposed Public Offering

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-GBT Appoints David Johnson As Chief Commercial Officer

* GBT APPOINTS INDUSTRY LEADER DAVID L. JOHNSON AS CHIEF COMMERCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics Q4 Loss Per Share $0.94

* GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

Select another date: